^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

R1530

i
Other names: R1530, RG1530
Associations
Trials
Company:
Roche
Drug class:
PDGFR inhibitor, PDGFR β antagonist, FLT3 inhibitor, VEGFR-2 inhibitor, FGFR1 inhibitor, VEGFR-3 inhibitor
Related drugs:
Associations
Trials
2years
Whole Transcriptome Sequencing Reveals Cancer-Related, Prognostically Significant Transcripts and Tumor-Infiltrating Immunocytes in Mantle Cell Lymphoma. (PubMed, Cells)
Similarly, high expression of MSTRG.153013.3, an overexpressed alternative transcript, was associated with shortened MCL survival...WTS results were cross-validated with qRT-PCR of selected transcripts as well as linear correlation analyses. In conclusion, expression levels of oncogenesis-associated transcripts and/or the ratios of microenvironmental immunocytes in MCL tumors may be used to improve prognostication, thereby leading to better patient management and outcomes.
Journal
|
CD8 (cluster of differentiation 8) • CCND1 (Cyclin D1) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • SOX11 (SRY-Box Transcription Factor 11) • VCAM1 (Vascular Cell Adhesion Molecule 1) • PCA3 (Prostate cancer associated 3)
|
CCND1 overexpression • CD8 expression • SOX11 expression
|
R1530
over3years
Allele-Specific MicroRNA-Mediated Regulation of a Glycolysis Gatekeeper PDK1 in Cancer Metabolism. (PubMed, Cancers (Basel))
The present study is the first to report the regulation of the PDK1 gene by miRNAs in an allele-dependent manner and highlights the role of PDK1 in metabolic adaption associated with PCa progression.
Journal
|
PDPK1 (3-Phosphoinositide dependent protein kinase 1)
|
R1530